MATTER 360 Doubles Impact, Repurposing 3.3 Million Pounds of Medical Surplus in 2021

MATTER (Minnesota-based global ) today announced, through the MATTER 360 initiative of repurposing medical equipment and supplies, that 3.3 million pounds of medical surplus was saved from landfills in 2021, an increase from 1.5 million pounds in 2020.

MATTER has been involved in repurposing medical equipment and supplies since 2002, and in the last three years alone, repurposed more than 5 million pounds.

MATTER repurposes medical equipment and supplies to aid people and reduce landfill non-hazardous medical waste, accomplishing this through distributions to international hospital and clinic partners, from resale efforts, and by recycling.

Established partnerships with hospitals and clinics provide MATTER the opportunity to repurpose medical supplies and equipment, which accounts for 90 percent of donations. As a result, medical equipment and supplies that are no longer useful in the United States, take on a renewed purpose around the globe.

Lisa Campbell, Director of Purchased Services Contracting at UnityPoint Health commented, “The most important thing is that we want to make a difference in people’s lives all over the world. We have this reach in Iowa, Illinois, and Wisconsin, but we want to touch more lives than that. This is such important work, being able to help organizations like MATTER with things that would otherwise go into the landfill, or we’d have to pay for someone to haul them away. It makes perfect sense to partner with you. It’s a wonderful relationship, our whole vision and purpose are to show people how much they matter, and what better way to do that than by partnering with MATTER.”

Of the remaining supplies and equipment received, MATTER remarkets approximately 4 percent via sales channels to support MATTER projects and operations. Unusable supplies and equipment, approximately 5 percent, is recycled annually, resulting in total waste of just 1%.

“We remain committed to helping our ever-growing number of partners, easily and efficiently, donate medical supplies and equipment to benefit others when no longer useful in their present location,” stated Joel Anderson, Executive VP of MATTER 360. “We greatly appreciate the trust that our partners, including hospital and clinics around the United States, place in us.”

SourceMATTER

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”